Sagimet Biosciences Inc.
SGMT
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabol…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$53M
▼ -12.0% YoY
Op. Margin
–
ROIC
-26.41%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$44M
▼ -7.6% YoY
Net Debt
-$234M
Net Cash Position
Cash & Equiv.
$236M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with SGMT
Held by ETFs
SGMT is in 13 US ETFs. The largest of them, with SGMT's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.13%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.02%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.04%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.03%of the fund
Sagimet Biosciences (SGMT) in three numbers
Questions about Sagimet Biosciences
Is Sagimet Biosciences a high-quality business?
Sagimet Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 2 checks computed from SEC filings. Its best check is net debt at -$234M, and its weakest is return on capital at -26.4%. The Quality tab shows every check against its target.
Does Sagimet Biosciences (SGMT) pay a dividend?
No. Sagimet Biosciences (SGMT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in SGMT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SGMT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.